Access expanding for experimental weight loss drug
Summary
Eli Lilly is increasing the availability of its experimental weight loss drug called retatrutide. This drug, still not approved by the FDA, helped obese patients in clinical trials lose between 73 and 85 pounds over two years.Key Facts
- The drug’s name is retatrutide.
- Retatrutide is currently experimental and not yet approved by the FDA.
- Eli Lilly is the company developing and expanding access to this drug.
- Clinical trial participants who took retatrutide lost 73 to 85 pounds over two years.
- Dr. Rachel Pessah Pollack has discussed details about the drug’s safety and who can use it.
- The information was presented on CBS News.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
